-
Patent Agency Ranking
公开(公告)号：US20140329862A1
公开(公告)日：2014-11-06
申请号：US14334718
申请日：2014-07-18
Applicant: Pfizer Inc.
Inventor： Gary Erik Aspnes , Mary Theresa Didiuk , Kevin James Filipski , Angel Guzman-Perez , Jeffrey Allen Pfefferkorn , Benjamin Dawson Stevens , Meihua Mike Tu
IPC: C07D213/82
CPC classification number: C07D405/12 , A61K31/44 , A61K31/4427 , C07D213/74 , C07D213/81 , C07D213/82 , C07D237/08 , C07D239/42 , C07D241/28 , C07D241/34 , C07D401/12 , C07D403/12
Abstract: The present invention provides a compound of Formula (I) or a pharmaceutically acceptable salt thereof wherein R1, R2, R3, A1, A2, A3, A4, L, B1, B2, B3 and B4 are as defined herein. The compounds of Formula I have been found to act as glucagon antagonists or inverse agonists. Consequently, the compounds of Formula I and the pharmaceutical compositions thereof are useful for the treatment of diseases, disorders, or conditions mediated by glucagon.
Abstract translation: 本发明提供式（I）化合物或其药学上可接受的盐，其中R1，R2，R3，A1，A2，A3，A4，L，B1，B2，B3和B4如本文所定义。 已经发现式I的化合物用作胰高血糖素拮抗剂或反向激动剂。 因此，式I化合物及其药物组合物可用于治疗由胰高血糖素介导的疾病，病症或病症。
-
公开(公告)号：US08859591B2
公开(公告)日：2014-10-14
申请号：US13934322
申请日：2013-07-03
Applicant: Pfizer Inc.
Inventor： Gary Erik Aspnes , Mary Theresa Didiuk , Kevin James Filipski , Angel Guzman-Perez , Esther Cheng Yin Lee , Jeffrey Allen Pfefferkorn , Benjamin Dawson Stevens , Meihua Mike Tu
IPC: A61K31/415 , A61K31/4427 , A61K31/497 , A61K31/501 , A61K31/506 , C07D231/00 , C07D233/00 , C07D237/06 , C07D239/24 , C07D241/10 , C07D233/61 , C07D231/54 , C07D207/34 , C07D487/04 , C07D403/12 , C07D249/08 , C07D231/16 , C07D231/14 , C07D233/68 , C07D231/12 , C07D249/06 , C07D233/84 , C07D405/14 , C07D401/12 , C07D403/04 , C07D233/64 , C07D231/18 , C07D401/14 , C07D261/08 , C07D401/04 , C07D231/56 , C07D233/70
CPC classification number: C07D401/04 , A61K31/506 , C07D207/34 , C07D231/12 , C07D231/14 , C07D231/16 , C07D231/18 , C07D231/54 , C07D231/56 , C07D233/61 , C07D233/64 , C07D233/68 , C07D233/70 , C07D233/84 , C07D239/28 , C07D249/06 , C07D249/08 , C07D261/08 , C07D401/12 , C07D401/14 , C07D403/04 , C07D403/12 , C07D405/14 , C07D487/04
Abstract: The present invention provides a compound of Formula (I) or a pharmaceutically acceptable salt thereof wherein R1, R2, R3, A1, A2, A3, A4, L, B1, B2, B3 and B4 are as defined herein. The compounds of Formula I have been found to act as glucagon antagonists or inverse agonists. Consequently, the compounds of Formula I and the pharmaceutical compositions thereof are useful for the treatment of diseases, disorders, or conditions mediated by glucagon.
Abstract translation: 本发明提供式（I）化合物或其药学上可接受的盐，其中R1，R2，R3，A1，A2，A3，A4，L，B1，B2，B3和B4如本文所定义。 已经发现式I的化合物用作胰高血糖素拮抗剂或反向激动剂。 因此，式I化合物及其药物组合物可用于治疗由胰高血糖素介导的疾病，病症或病症。
-
公开(公告)号：US09073871B2
公开(公告)日：2015-07-07
申请号：US14471576
申请日：2014-08-28
Applicant: Pfizer Inc.
Inventor： Gary Erik Aspnes , Mary Theresa Didiuk , Kevin James Filipski , Angel Guzman-Perez , Esther Cheng Yin Lee , Jeffrey Allen Pfefferkorn , Benjamin Dawson Stevens , Meihua Mike Tu
IPC: A61K31/415 , C07D231/12 , C07D207/34 , C07D231/14 , C07D231/16 , C07D231/18 , C07D231/54 , C07D231/56 , C07D233/61 , C07D233/64 , C07D233/68 , C07D233/70 , C07D233/84 , C07D249/06 , C07D249/08 , C07D261/08 , C07D401/04 , C07D401/12 , C07D401/14 , C07D403/04 , C07D405/14 , C07D487/04 , C07D403/12
CPC classification number: C07D401/04 , A61K31/506 , C07D207/34 , C07D231/12 , C07D231/14 , C07D231/16 , C07D231/18 , C07D231/54 , C07D231/56 , C07D233/61 , C07D233/64 , C07D233/68 , C07D233/70 , C07D233/84 , C07D239/28 , C07D249/06 , C07D249/08 , C07D261/08 , C07D401/12 , C07D401/14 , C07D403/04 , C07D403/12 , C07D405/14 , C07D487/04
Abstract: The present invention provides a compound of Formula (I) or a pharmaceutically acceptable salt thereof wherein R1, R2, R3, A1, A2, A3, A4, L, B1, B2, B3 and B4 are as defined herein. The compounds of Formula I have been found to act as glucagon antagonists or inverse agonists. Consequently, the compounds of Formula I and the pharmaceutical compositions thereof are useful for the treatment of diseases, disorders, or conditions mediated by glucagon.
-
公开(公告)号：US20150099882A1
公开(公告)日：2015-04-09
申请号：US14564263
申请日：2014-12-09
Applicant: Pfizer Inc.
Inventor： Mary Didiuk , Kevin J. Filipski , Angel Guzman-Perez , Esther C. Lee , Jeffrey A. Pfefferkorn , Benjamin Stevens , Meihua Tu
IPC: C07D241/44 , C07D217/22 , C07D215/38 , C07D239/84
CPC classification number: C07D239/84 , A61K31/517 , C07D215/38 , C07D217/22 , C07D239/94 , C07D241/44
Abstract: The present invention provides a compound of Formula I or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, A1, A2, A3, B1, B2, B3 and B4 are as defined herein. The compounds of Formula I have been found to act as glucagon antagonists or inverse agonists. Consequently, the compounds of Formula I and the pharmaceutical compositions thereof are useful for the treatment of diseases, disorders, or conditions mediated by glucagon.
-
公开(公告)号：US08933104B2
公开(公告)日：2015-01-13
申请号：US14334718
申请日：2014-07-18
Applicant: Pfizer Inc.
Inventor： Gary Erik Aspnes , Mary Theresa Didiuk , Kevin James Filipski , Angel Guzman-Perez , Jeffrey Allen Pfefferkorn , Benjamin Dawson Stevens , Meihua Mike Tu
IPC: C07D401/12 , A61K31/44 , C07D213/82
CPC classification number: C07D405/12 , A61K31/44 , A61K31/4427 , C07D213/74 , C07D213/81 , C07D213/82 , C07D237/08 , C07D239/42 , C07D241/28 , C07D241/34 , C07D401/12 , C07D403/12
Abstract: The present invention provides a compound of Formula (I) or a pharmaceutically acceptable salt thereof wherein R1, R2, R3, A1, A2, A3, A4, L, B1, B2, B3 and B4 are as defined herein. The compounds of Formula I have been found to act as glucagon antagonists or inverse agonists. Consequently, the compounds of Formula I and the pharmaceutical compositions thereof are useful for the treatment of diseases, disorders, or conditions mediated by glucagon.
-
-
-
-
Search Results
15
records
(took 0.027 seconds)
